SERA PROGNOSTICS INC-A

$1.66 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About SERA PROGNOSTICS INC-A

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Stock Analysis

last close $1.69
1-mo return 28%
3-mo return -53.3%
avg daily vol. 209.26T
52-week high 15.5
52-week low 1.15
market cap. $50M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 55.2%
baraka

Subscribe now for daily local and international financial news

Subscribe